Dechra Pharmaceuticals PLC AGM Trading Update (5785E)
19 October 2018 - 5:00PM
UK Regulatory
TIDMDPH
RNS Number : 5785E
Dechra Pharmaceuticals PLC
19 October 2018
Friday, 19 October 2018
Dechra(R) Pharmaceuticals PLC
(Dechra, Group, Company)
AGM Trading update
The Board of Dechra issues the following update prior to the
Annual General Meeting (AGM) which will take place at 10.30 am
today, Friday 19 October 2018, at the offices of DLA Piper, 160
Aldersgate, London, EC1A 4HT.
The Company is pleased to report that performance in the first
quarter of our financial year was in line with management's
expectations, with continued year on year above market growth in
both EU Pharmaceuticals and NA Pharmaceuticals. The Board is
confident in achieving its expectations for the current financial
year, and in the continued out-performance of the markets in which
it operates. We remain confident that Dechra and its proven
strategy is well placed to sustain growth.
Separately the Group announces today the acquisition of the
entire share capital of Laboratorios Vencofarma do Brasil Ltda
("Venco"). To read, please follow the link
http://www.rns-pdf.londonstockexchange.com/rns/5785E_1-2018-10-19.pdf
No other new trading updates are to be made at the AGM
today.
Dechra will announce its interim results for the six month
period to 31 December 2018 on 25 February 2019.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606 814
730
Richard Cotton, Chief Financial Officer Office: +44 (0) 1606 814
e-mail: corporate.enquiries@dechra.com 730
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703
e-mail: fiona@tooleystreet.com 523
Office: +44 (0) 121 309
0099
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and relates products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTLIFFSIFLALIT
(END) Dow Jones Newswires
October 19, 2018 02:00 ET (06:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024